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Conclusion: Presentation with ACS is a significant risk factor for HOPR. Platelet
reactivity testing should focus on such high-risk patients.
TCT-181
Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for
Bleeding During Dual Antiplatelet Therapy
Miltiadis Papalexandris, Hubertus Degen, Carsten Stoepel, Thomas Lickfeld,
Thorsten Schneider, Carlos Freitas, Michael Haude
Städtische Kliniken Neuss, Academic Hospital University of Düsseldorf, Neuss,
Germany
Background: Drug eluting stent implantation in patients with high risk for bleeding
is a relative clinical contraindication according to recent guidelines of the European
Society of Cardiology. On the other hand, the stent restenosis limits 20-30% of
percutaneous coronary interventions with bare metal stents implantations. Our aim is
to examine the outcome of CD 34 antibody coated stent (GENOUS, Orbus Neich) in
a group of patient with high risk for bleeding during prolonged dual antiplatelet therapy.
Methods: In our database we have identified, 61 consecutive patients with mean age
65,5±19 years, who electively received a GENOUS stent during the period June 2006
to July 2009, in whom dual antiplatelet therapy* (*DAPT: Aspirin 100mg and
Clopidogrel 75mg) had to be limited for various periods due to accompanied diseases
and/or surgical needs. The survey excluded patients with STEMI and NSTEMI. 35
patients (57%) had DAPT for a maximum of 4 weeks while 26 patients (43%) had a
DAPT of 2 to 12 months.
Results: Please find attached the results
Results
* Target lesion revascularisation
**Major adverse cardiac events
Conclusion: In patients with contraindications to long antiplatelet therapy for
accompanying diseases, GENOUS Stent demonstrates a good alternative and is
associated with significant benefits in terms of TLR and stent thrombosis. Thus until
the results of further large randomized trials with long-term follow up become
available, GENOUS stent may be considered among patients with high risk of bleeding
undergoing primary angioplasty.
TCT-182
On-Treatment Platelet Reactivity Before Coronary Artery Bypass Surgery is
Associated with In-Hospital Major Bleeding. Results of a Prospective
Evaluation
Gabriel L Sardi, Michael A Gaglia, Ana Laynez-Carnicero, Gabriel Maluenda,
Israel Barbash, Itsik Ben-Dor, Manuel A Gonzalez, Rebecca Torguson, Camille
Hauville, Rajbabu Pakala, Zhenyi Xue, William O Suddath, Kenneth M Kent, Lowell
F Satler, Augusto D Pichard, Joseph Lindsay, Ron Waksman
Cardiology Dept., Washington Hospital Center, Washington, DC
Background: CABG surgery within 5 days of antiplatelet treatment discontinuation
is controversial. We aimed to evaluate the association of on-treatment platelet reactivity
before CABG and in-hospital major bleeding (IHMB).
Methods: On-treatment platelet reactivity was prospectively measured with Verify
Now (VN) P2Y12 assay, Vasodilator Stimulated Phosphoprotein Phosphorylation
(VASP) and Light Transmittance Aggregometry (LTA) with 5 and 20 μM of ADP, in
51 patients undergoing CABG within 5 days of thienopyridine discontinuation, from
08/2010 to 05/2011. The primary endpoint was IHMB, defined as bleeding
intracranially, or that associated with hemodynamic compromise, a hemoglobin (Hb)
drop of >5g/dl, or a hematocrit drop of >15%. We assessed the relation between platelet
reactivity value and IHMB with Wilcoxon rank-sum test and its relation with Hb drop
with Spearman correlation.
Results: Average age was 62 years. Thirty patients (58.8%) had major bleeding. Only
VASP and LTA 5 μM of ADP were associated with the primary endpoint (p=0.001 and
0.03, respectively). Median VASP platelet reactivity index (PRI) was 56.7% in patients
with IHMB and 73.7% in those without. The respective values of maximal platelet
aggregation percentage by LTA 5 μM were 39% and 48%. VN P2Y12 reaction units
and VASP PRI were inversely correlated to the degree of hemoglobin drop after CABG
(p= 0.0006 and 0.0012, respectively).
Conclusion: Platelet reactivity testing with VASP and LTA 5 μM of ADP before CABG
is associated with IHMB. These tests could be used to risk stratify patients undergoing
CABG within 5 days of thienopyridine discontinuation.
TCT-183
The impact of paraoxonase-1 activity on the incidence of intra-stent thrombus
after drug-eluting stent implantation in the Japanese CYP2C19*2 carriers
receiving clopidogrel
Ryo Nishio, Junya Shite, Toshiro Shinke, Hiromasa Otake, Masayuki Nakagawa,
Ryoji Nagoshi, Amane Kozuki, Takumi Inoue, Hirotoshi Hariki, Tsuyoshi Osue, Yu
Taniguchi, Masamichi Iwasaki, Noritoshi Hiranuma, Akihide Konishi, Hiroto
Kinutani, Yoko Haraguchi, Tatsuro Ishida, Ken-ichi Hirata
Kobe University, Kobe city, Japan
Background: The impact of paraoxonase-1 (PON1) activity and PON1 gene
polymorphism on the efficacy of clopidogrel has not been clarified. The aim of this
study was to assess the association of PON1 activity and the incidence of intra-stent
thrombus after drug-eluting stent (DES) implantation in the Japanese CYP2C19*2
carriers and non-carriers receiving clopidogrel.
Methods: This study included 48 Japanese patients who underwent optical coherence
tomography (OCT) examination for the evaluation of intra-stent thrombus 8 months
after DES implantation. The patients were chronically treated with clopidogrel
(75mg/day) and aspirin (100mg/day). The CYP2C19 genotype was analyzed by
polymerase chain reaction and the PON1 activity was evaluated by spectrophotometric
assay. The patients were divided into two groups; those with at least one CYP2C19*2
allele (*2 carriers) and non-carriers.
Results: In 48 Japanese patients, 19 patients were *2 carriers. In *2 carriers, the
incidence of intra-stent thrombus was 52.6% (p=0.03 vs non-carriers). The PON1
activity was lower in *2 carriers with intra-stent thrombus than those without intra-
stent thrombus (178±53 U/L vs 257±102 U/L, p=0.04). In non-carriers, the incidence
of intra-stent thrombus was less (20.7%), and the PON1 activity was not different
between non-carriers with intra-stent thrombus or those without intra-stent thrombus
(227±35 U/L vs 226±102 U/L, p>0.99).
Conclusion: The PON1 activity influenced the incidence of intra-stent thrombus in
CYP2C19*2 carriers, but did not influence that in non-carriers. This study suggested
that the PON1 activity may have an impact on clopidogrel efficacy in Asians, because
of the high frequency of CYP2C19*2 polymorphism.
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